Curis, Inc., a biotechnology company, focuses on developing and commercializing drug candidates for the treatment of human cancers. CUDC-907 The company’s most advanced drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC), and phosphatidylinositol-3-kinase (PI3K) enzymes, which has completed the dose escalation stage of a first-in-man Phase 1 clinical study in patients with relapsed, refractory lymphoma or multiple myeloma. In addition, the company entered into a multi-year collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited (Aurigene), a specialized, discovery stage biotechnology company and wholly-owned subsidiary of Dr. Reddy’s Laboratories. In 2013, the company initiated a Phase 1 clinical study of CUDC-907 in patients with relapsed or refractory lymphomas or multiple myeloma. In 2014, the company established the recommended Phase 2 dose and schedules of administration for further development of CUDC-907, and initiated enrollment of patients primarily with diffuse large B-cell lymphoma (DLBCL) or multiple myeloma in the expansion stage of the Phase 1 study. Development of CUDC-907 in hematological malignancies is partially supported under collaboration with The Leukemia & Lymphoma Society (LLS). In 2014, the company initiated a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with hormone receptor positive breast cancer or with NUT midline carcinoma. CUDC-427 The company’s proprietary pipeline also includes CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins, which has completed dose escalation in a Phase 1 clinical trial in patients with solid tumors or lymphoma. In 2012, the company licensed from Genentech Inc. (Genentech) the exclusive, worldwide rights for the development and commercialization of CUDC-427. Under the terms of the license agreement, the company has the sole right and responsibility for all research, development, manufacturing and commercialization activities related to CUDC-427. Other The company also regained rights to its Heat Shock Protein 90 (HSP90), inhibitor Debio 0932 from Debiopharm International S.A. (Debiopharm). The company has redesignated this drug candidate as CUDC-305 and is in the process of evaluating initiating clinical studies with CUDC-305 in 2015. The company’s collaborators F. Hoffmann-La Roche Ltd (Roche) and Genentech are commercializing Erivedge (vismodegib), a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, in advanced basal cell carcinoma (BCC). Erivedge Erivedge is the United States Food and Drug Administration (FDA) approved medicine for treatment of metastatic or locally advanced basal cell carcinoma (BCC), and is being developed and commercialized by Roche and Genentech under a collaboration agreement between the company and Genentech. In 2012, the FDA approved Erivedge for treatment of adults with BCC that has spread to other parts of the body, or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation, collectively considered as advanced BCC. Intellectual Property In the U.S., as of December 31, 2014, the company had 94 issued or allowed patents expiring on various dates between 2015 and 2033, as well as various pending patent applications. Research and Development As of December 31, 2014, the company incurred expenses of $13,659,000 on research and development activities. History Curis, Inc. was founded in 2000 as a Delaware corporation.
curis inc (CRIS:NASDAQ GM)
4 Maguire Road
Lexington, MA 02421
|ArQule Inc||$1.62 USD||+0.06|
|CTI BioPharma Corp||$1.98 USD||-0.04|
|Cytokinetics Inc||$6.35 USD||-0.17|
|Exelixis Inc||$3.44 USD||-0.05|
|Navidea Biopharmaceuticals Inc||$1.68 USD||+0.06|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CURIS INC, please visit www.curis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.